Athens, Greece & San Diego, California, May 7, 2026 — BIOEMTECH, a preclinical CRO with a focus on in vivo radiopharmaceutical research and developer of 3D PET and SPECT alpha-emitter imaging systems for preclinical and translational research, and CERTIS Oncology, an AI-enabled precision oncology and translational science company, today announced a strategic collaboration to offer integrated patient-derived xenograft (PDX) access for radiopharmaceutical preclinical studies conducted at BIOEMTECH facilities.
Under the agreement, CERTIS Oncology will supply study-ready PDX avatars representing diverse tumor types and molecular profiles. These models will be available for functional testing within BIOEMTECH’s preclinical PET/SPECT imaging workflows, enabling sponsors and academic partners to evaluate targeted radiotherapeutics and radiotracers with higher translational relevance.
“Access to robust, clinically relevant patient-derived models is essential to bridge preclinical findings to the clinic”, said Nick Afentoulides, Vice President Business Development of BIOEMTECH. “Partnering with Certis Oncology strengthens our ability to serve our Sponsors and deliver end‑to‑end preclinical in vivo solutions — from model selection and imaging to quantitative analysis — accelerating and derisking radiopharmaceutical development”.
“Radiopharma programs involve complex, multi-variable relationships between target expression, tumor biology, and therapeutic response. That makes them particularly challenging to translate—and well-suited for predictive modeling and rigorous validation in clinically relevant patient-derived models”, said Peter Ellman, President and CEO of CERTIS Oncology. “Combining our strengths with BIOEMTECH’s radiopharmaceutical capabilities provides sponsors with more predictive preclinical data to inform clinical strategy”.
Key elements of the collaboration:
- Model access: A curated library of CERTIS PDX models covering key tumor indications and molecular subtypes, selectable for single or multiplexed studies.
- Integrated workflows: Coordinated planning, implantation, imaging, and quantitative analysis using BIOEMTECH’s PET/SPECT platforms and study services.
- Study support: Study design assistance, shared data packages to support reproducibility and regulatory discussions.
- Timeline and availability: Collaborative studies to begin immediately; model-specific availability and study timelines will be coordinated per project.
The partnership is expected to benefit pharmaceutical and biotech sponsors, academic investigators, and translational research groups seeking more predictive preclinical evaluation of radiopharmaceuticals.
About BIOEMTECH
BIOEMTECH is a preclinical CRO with a focus on in vivo radiopharmaceutical research and also develops 3D PET and SPECT alpha-emitter imaging systems for preclinical and translational research. BIOEMTECH’s services and imaging systems support pharmaceutical, biotech, and academic researchers in advancing radiopharmaceuticals, molecular imaging and therapeutic development.
About Certis Oncology
CERTIS Oncology is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. By integrating predictive modeling, dynamic exploration of biological and molecular datasets, and functional validation in clinically relevant patient-derived cancer models, CERTIS generates Oncology Intelligence®—highly predictive, decision-ready insights that help pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.
Founded in 2016, CERTIS operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in San Diego’s Sorrento Valley life sciences hub.
Media contacts
BIOEMTECH
Nick Afentoulides
Vice President, Business Development
203-515-1443
nafentoulides@bioemtech.com
CERTIS Oncology
Kristein King
Chief Marketing Officer
+1 858-952-1820
kking@certisoncology.com